Alliance Pharma Investors - APH

Alliance Pharma Investors - APH

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type
Alliance Pharma Plc APH London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
-0.20 -0.2% 101.80 16:35:14
Open Price Low Price High Price Close Price Previous Close
103.20 100.20 103.20 101.80 102.00
more quote information »
Industry Sector

Top Investor Posts

2vdm: The recorded webcast will also be made available at the investor section of Alliance's website, hxxps://
2vdm: RNSthis a.m.: Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the 12 months ended 31 December 2020 on Tuesday 23 March 2021. A conference call for analysts will be held at 10.30am on 23 March 2021; analysts who require dial-in details, please contact Buchanan at A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 23 March 2021 at this link: hxxps:// The recorded webcast will also be made available at the investor section of Alliance's website, hxxps:// For more information, please contact Buchanan on 020 7466 5000 or email
amunro: Tesla is an interesting one. Are they are a car maker or innovator of next gen technology like self driving cars and batteries? As an investor sometimes you just need to follow the market, make money, with the view to getting out when things dive. Its all about managing risk. I got out of APH as I want the money to grow faster than APH offers.
amunro: Seems the investors are dead on this one... Anyone still there?
scillyfool: 2vdm, I'm sure APH have their eyes on prospective struggling competitors, but as the integration of Nizoral won't be completed uhtil June I just thought that they should concentrate on getting that integrated before taking on further acquisitions. My own thoughts are that in future many previous company development strategies may need to be rethought. First priority - survival. A company with no debt and a cash pile can better survive any market shocks and not only keep investors happy by continuing to pay dividends, but perhaps be even better placed to buy struggling competitors. Let's hope that after all this Covid-19 is over APH pay a special dividend to their loyal shareholders equal to the pulled final dividend to reassure us.
scillyfool: I think we are going to see a changed world after the Corona virus is defeated. This may be the time for Alliance to take a step back in terms of acquisitions and consolidate their financial position. Investors in future will be looking to invest in companies with little or no debt for a few years. Conserving cash is a sensible move provided it is used wisely by paying down debt.
2vdm: This was a post last year in Investors Chronicle: "The only cloud comes from a Competition and Markets Authority (CMA) investigation into the price of one of the medicines Alliance licenses to another company. Alliance denies that it has any involvement in the pricing of prochlorperazine, which generated less than £0.2m of revenue in 2018, so this case shouldn’t cause investors to lose too much sleep. But a clampdown by the CMA on drug price inflation is not good news" Given that APH's turnover is circa £118 million, it's hardly a major issue, although I understand winning's comment above. My view as a LTH is that if the price takes a hit in the event that the CMA rules against it and institutions dump stock, then it will be a wonderful buying opportunity for the long term. Just my view.
mazarin: The ‘flip side’ is that any hint of bad news and APH plummets like a stone before you can do anything about it. I think it’s the rather unusual profile of the major APH investors. A lot are held by Institutions and family connected Investors. Institutions take time to analyse results before adding, but will ‘drop’ instantly whenever there’s any possible hint of trouble. Regardless of whether the rumour is justified or within ‘the gift’ of the company. I’ve experienced many of examples during my years of holding, the Sanofi Pasteur flood disaster years ago and more recently the ‘price fixing’ enquiry, each took it’s toll on the share price that takes a long time to recover.
winnings1: Marksp2011 / Investors/researchers residing in Bangladesh do not seem to share your concerns, the share price there is well above the share price here. As far as I can see BXP is a standalone company commercially linked to a distribution company with the latter operated by a related party - this link seems very successful/fruitful, bringing a constant flow of new outlets.
winnings1: Further to my last message, BXP'# share price on the Dhaka stock exchange is substantially higher than the trading price here. Clearly investors based in Bangladesh do like the shares and have the fullest confidence in the direction the Company is going. There is no indication of BXP being part of a larger concern, BXP stands on its own and conforms to the Dhaka Stock Exchange Rules, which are certainly no slack. I hold BXP long term, and plan to buy more.
ADVFN Advertorial
Your Recent History
Alliance P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211128 03:34:53